Abstracts tagged "Autoantibodies and dermatomyositis"

Abstract Number: 1259 • 2014 ACR/ARHP Annual Meeting
A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody
Shinji Sato¹, Akihiro Murakami², Akiko Kuwajima³, Kazuhiko Takehara⁴, Tsuneyo Mimori⁵, Atsushi Kawakami⁶, Michiaki Mishima⁷, Takafumi Suda⁸, Mariko Seishima⁹, Manabu Fujimoto¹⁰ and Masataka Kuwana¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Dermatology, Kanazawa University, Kanazawa, Japan, ⁵Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁶Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ¹⁰Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM) and…
Abstract Number: 1258 • 2014 ACR/ARHP Annual Meeting
Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity
Manabu Fujimoto¹, Akihiro Murakami², Shunsuke Kurei², Akiko Kuwajima³, Yasuhiro Fujisawa¹, Atsushi Kawakami⁴, Michiaki Mishima⁵, Shinji Sato⁶, Mariko Seishima⁷, Takafumi Suda⁸, Tsuneyo Mimori⁹, Kazuhiko Takehara¹⁰ and Masataka Kuwana¹¹, ¹Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁶Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹⁰Dermatology, Kanazawa University, Kanazawa, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-transcriptional intermediary factor 1 (TIF-1) and anti-Mi-2 antibodies (Abs) are myositis-specific autoantibodies (MSA) selectively detected in dernatomyositis (DM) patients. Anti-TIF-1 Ab is frequently found…
Abstract Number: 226 • 2012 ACR/ARHP Annual Meeting
Autoantibodies to Small Ubiquitin-Like Modifier Activating Enzymes in Japanese Patients with Dermatomyositis
Manabu Fujimoto¹, Takashi Matsushita², Yasuhito Hamaguchi³, Kenzo Kaji³, Minoru Hasegawa¹ and Kazuhiko Takehara⁴, ¹Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ²Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ³Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Myositis-specific autoantibodies (MSAs) are closely associated with distinct clinical subsets within idiopathic inflammatory myopaties, and thus serve as useful diagnostic tools. Recently, anti-small ubiquitin-like modifier…
Abstract Number: 1953 • 2012 ACR/ARHP Annual Meeting
Antibodies to NXP-2 and Transcriptional Intermediary Factor-Gamma Identify Patients with Cancer-Associated Dermatomyositis
David Fiorentino¹, Lisa Christopher-Stine², Lorinda Chung³, Bharathi Lingala⁴, Andrew L. Mammen⁵, Antony Rosen⁶ and Livia Casciola-Rosen⁶, ¹Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ⁴Dermatology, Stanford University, Redwood City, CA, ⁵NIAMS, NIH, Bethesda, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is known to be associated with internal malignancy, and identifying patients at high risk is a high priority. Recently, several groups have…
Abstract Number: 1954 • 2012 ACR/ARHP Annual Meeting
Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients
David Fiorentino¹, Lorinda Chung², Lisa Zaba¹, Bharathi Lingala³, Antony Rosen⁴ and Livia Casciola-Rosen⁴, ¹Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ³Dermatology, Stanford University, Redwood City, CA, ⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Myositis-specific antibodies have been proposed as tools for disease classification as they are correlated with certain clinical and genetic features. Recently, two new DM-specific…